Castle Biosciences Presents Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting


Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data were featured in two oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, Oct. 9-11, 2020.


DecisionDx®-Melanoma: Skin Cancer and Reconstruction Session; Friday, October 9, 2020


“Cutaneous Melanoma Prognostic Model Combining 31-gene Expression Profile and Sentinel Lymph Node Biopsy” was presented by Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas.


DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.


“As most sentinel lymph node biopsies are negative, there is a need to identify which melanoma patients can forgo sentinel lymph node biopsy (SNLB),” said Dr.

Read More

Castle Biosciences to Present Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

Oral presentations to highlight both commercially available skin cancer prognostic tests

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, October 9-11, 2020.

Presentation details are as follows:

Title: Clinical validation and incorporation of a prognostic 40-gene expression profile test into clinicopathological risk assessment for cutaneous squamous cell carcinoma (cSCC)
Session: Skin Cancer & Reconstruction
Presenter: Sherrif Ibrahim M.D., Ph.D., associate professor, University of Rochester Medical Center
Date: Friday, October 9, 2020
Time: 6:24 p.m. – 6:27 p.m. ET

Title: Cutaneous melanoma prognostic model combining 31-gene expression profile and sentinel lymph node biopsy
Session: Skin Cancer & Reconstruction
Presenter: Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas
Date: Friday, October 9, 2020
Time: 6:30 p.m. –

Read More